- Home
- CITE vs QNCX Comparison
CITE vs QNCX Comparison
Compare CITE & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CITE
- QNCX
- Stock Information
- Founded
- CITE 2021
- QNCX 2012
- Country
- CITE United States
- QNCX United States
- Employees
- CITE N/A
- QNCX N/A
- Industry
- CITE
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CITE
- QNCX Health Care
- Exchange
- CITE NYSE
- QNCX Nasdaq
- Market Cap
- CITE 93.6M
- QNCX 92.3M
- IPO Year
- CITE 2022
- QNCX 2019
- Fundamental
- Price
- CITE $11.68
- QNCX $1.75
- Analyst Decision
- CITE
- QNCX Strong Buy
- Analyst Count
- CITE 0
- QNCX 4
- Target Price
- CITE N/A
- QNCX $9.50
- AVG Volume (30 Days)
- CITE 35.0K
- QNCX 209.4K
- Earning Date
- CITE 01-01-0001
- QNCX 11-13-2024
- Dividend Yield
- CITE N/A
- QNCX N/A
- EPS Growth
- CITE N/A
- QNCX N/A
- EPS
- CITE N/A
- QNCX N/A
- Revenue
- CITE N/A
- QNCX N/A
- Revenue This Year
- CITE N/A
- QNCX N/A
- Revenue Next Year
- CITE N/A
- QNCX N/A
- P/E Ratio
- CITE N/A
- QNCX N/A
- Revenue Growth
- CITE N/A
- QNCX N/A
- 52 Week Low
- CITE $10.89
- QNCX $0.51
- 52 Week High
- CITE $12.25
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CITE 60.80
- QNCX 46.26
- Support Level
- CITE $11.61
- QNCX $1.80
- Resistance Level
- CITE $11.75
- QNCX $1.96
- Average True Range (ATR)
- CITE 0.03
- QNCX 0.20
- MACD
- CITE -0.01
- QNCX -0.06
- Stochastic Oscillator
- CITE 60.00
- QNCX 12.50
About CITE CARTICA ACQUISITION CORP
Cartica Acquisition Corp is a blank check company.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.